| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Cervicalcancer and its precursor lesion,cervicalintraepithelial neoplasia grade3(CIN3)are a mucosal precancerous lesion caused by high-riskHPV.Induction ofimmunological clearance ofCIN3 by targetingHPV antigens is a strategy for CIN3therapy.We've evaluated the clinical efficacy of an attenuated Lactobacillus casei expressing HPV16E7,GLBL101c,in patients with HPV16-associatedCIN3.GLBL101c had a regression onCIN3to CIN2,but the efficacy remained partial.So we developed next generation E7-expressing Lactobacillus-basedvaccine to improve induction ofmucosalimmune responses to HPVE7.
1)TheJapanese herbalmedicines,JuzenTaihoTo(JTT)/HochuEkkiTo(HET)showed the synergy ofan oralLactobacillus-based vaccine on mucosalimmune responses.2)0.3μgofE7in1.2x10~8cells ofLactobacilluscasei wasthe most effective dose forimmunological inducibility with 2-fold higher thanthe existing,GLBL101c.The optimized newcancer-vaccine with increased pharmacologicaleffect will be a reliable drug for treatmentofCIN2-3.
|
